(function(){var loadHandler=window['sl_{D0ADD9BC-5BCE-4B01-85F9-188A7AEC90E6}'];loadHandler&&loadHandler(164, '<div id="spr0_aef7f07"><div id="spr1_aef7f07" class="kern slide"><img id="img2_aef7f07" src="data/img2.png" width="720px" height="540px" alt="" style="left:0px;top:0px;"/></div><div id="spr2_aef7f07" class="kern slide"><div id="spr3_aef7f07" style="left:47.001px;top:187.442px;"><img id="img0_aef7f07" src="data/img161.jpg" width="184.5" height="225" alt="" style="left:0.052px;top:0.12px;"/></div><div id="spr4_aef7f07" style="left:0px;top:5.86px;"><div style="width:0px;"><span id="txt0_aef7f07" class="relpos" data-width="341.375000" style="left:37.709px;top:-0.448px;">Activating mutations in ER</span><span id="txt1_aef7f07" class="relpos" style="left:37.704px;top:-0.448px;">α</span><span id="txt2_aef7f07" class="relpos" data-width="57.781250" style="left:37.699px;top:-0.448px;"> LBD</span></div></div><div id="spr5_aef7f07" style="left:95.749px;top:416.339px;"><div style="width:0px;"><span id="txt3_aef7f07" data-width="67.882813" style="left:7.621px;top:3.448px;">PDB 1QKU</span></div></div><div id="spr6_aef7f07" style="left:414.238px;top:499.583px;"><div style="width:0px;"><span id="txt4_aef7f07" data-width="192.117188" style="left:21.372px;top:2.082px;">Toy et al 2013 Nat Genetics 45:1439-45</span></div><div style="width:0px;"><span id="txt5_aef7f07" data-width="207.000000" style="left:13.927px;top:16.482px;">Toy et al 2017 Cancer Discov; 7(3); 277–87</span></div></div><div id="spr7_aef7f07" style="left:20.956px;top:506.853px;"><div style="width:0px;"><span id="txt6_aef7f07" data-width="219.714844" style="left:8.172px;top:2.082px;">Gangloff M, J Biol Chem. 2001, 276:15059-65</span></div></div><div id="spr8_aef7f07" style="left:420.331px;top:463.093px;"><div style="width:0px;"><span id="txt7_aef7f07" class="relpos" data-width="125.972656" style="left:8.274px;top:0.058px;">Y537S LBD </span><span id="txt8_aef7f07" class="relpos" data-width="79.789063" style="left:8.269px;top:0.058px;">w/o E2</span></div></div><div id="spr9_aef7f07" style="left:64.053px;top:463.093px;"><div style="width:0px;"><span id="txt9_aef7f07" class="relpos" data-width="86.283203" style="left:7.928px;top:0.058px;">wt LBD </span><span id="txt10_aef7f07" class="relpos" data-width="48.138672" style="left:7.923px;top:0.058px;">+ E2</span></div></div><div id="spr10_aef7f07" style="left:276.208px;top:174.615px;"><img id="img1_aef7f07" src="data/img162.jpg" width="444" height="274.5" alt="" style="left:-0.078px;top:0.109px;"/></div><div id="svg0_aef7f07" style="left:274.1px;top:178.686px;"><svg width="31" height="32" viewBox="0 0 31 32"><path fill="#ffffff" d="M0,0 h30.54 v31.544 h-30.54 Z"/></svg></div><div id="spr11_aef7f07" style="left:-0px;top:100.252px;"><div style="width:0px;"><span id="txt11_aef7f07" class="relpos" data-width="88.795898" style="left:29.535px;top:1.323px;">Detected in </span><span id="txt12_aef7f07" class="relpos" data-width="94.491211" style="left:29.53px;top:1.323px;">at least 10% </span><span id="txt13_aef7f07" class="relpos" data-width="127.749023" style="left:29.525px;top:1.323px;">of ER+ve BC with </span><span id="txt14_aef7f07" class="relpos" data-width="65.276367" style="left:29.52px;top:1.323px;">acquired</span><span id="txt15_aef7f07" class="relpos" data-width="286.171875" style="left:29.515px;top:1.323px;"> resistance during endocrine treatment</span></div><div style="width:0px;"><span id="txt16_aef7f07" data-width="524.408203" style="left:98.36px;top:22.923px;">Detected in &lt;1% of primary ER+ve tumours before endocrine treatment</span></div></div><div id="spr12_aef7f07" style="left:-0px;top:57.703px;"><div style="width:0px;"><span id="txt17_aef7f07" data-width="414.925781" style="left:153.42px;top:0.564px;">Example a secondary / acquired resistance</span></div></div></div></div>');})();